AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26265520 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyPill (daily single dose consisting of aspirin, valsartan, atorvastatin, and hydrochlorthiazide)
Number of subjects: 2400
Study 26265520 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2400
Study 23766359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg/m(2) administered orally, once daily, continuously for 28-day treatment cycles (with possible escalation to 150 mg/m(2)/d after two cycles).
Number of subjects: 16
Study 23766359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib treatment.
Number of subjects: 16
Study 21424043 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic diagnosis (PDD)
Number of subjects: 44
Study 21424043 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (WLC)
Number of subjects: 44
Study 18415952 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 648
Study 18415952 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 648
Study 16596105 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate supplementation (0.3 g/kg body mass/day for 5 days)
Number of subjects: 17
Study 16596105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16596105 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate supplementation
Number of subjects: 17
Study 12384627 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR stent implantation
Number of subjects: 0
Study 12384627 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold-plated NIR stent
Number of subjects: 0
Study 9665902 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 3744
Study 9665902 — intervention group
Group type: COMPARATOR
Intervention: Faecal occult blood testing
Number of subjects: 3744
Study 9665902 — intervention group
Group type: COMPARATOR
Intervention: Both tests combined
Number of subjects: 3744
Study 7930281 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (measured by body mass index)
Number of subjects: 692
Study 7930281 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 692
Study 7930281 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 692
Study 7930281 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy
Number of subjects: 692
Study 2502955 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms
Number of subjects: 12
Study 2502955 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms
Number of subjects: 12
Study 2502955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1219183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of synthetic secretin
Number of subjects: 10
Study 1219183 — intervention group
Group type: COMPARATOR
Intervention: Pernasal administration of synthetic secretin (snuff)
Number of subjects: 10
Study 7399873 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol and diuretics for the first eight weeks
Number of subjects: 66
Study 7399873 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus diuretics for the second eight weeks
Number of subjects: 66
Study 7399873 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics for the first eight weeks
Number of subjects: 66
Study 7399873 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics for the second eight weeks
Number of subjects: 66
Study 7399873 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol and diuretics in reverse order for Group 2
Number of subjects: 66
Study 30545780 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ixazomib (3 mg initially, increased to 4 mg from cycle 5 if tolerated)
Number of subjects: 656
Study 30545780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656
Study 30545780 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ixazomib
Number of subjects: 656
Study 29607860 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal infiltration anesthesia
Number of subjects: 40
Study 29607860 — intervention group
Group type: COMPARATOR
Intervention: Inferior alveolar nerve block (IANB)
Number of subjects: 40
Study 26219614 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1.5 μg kg min(‐1))
Number of subjects: 20
Study 26219614 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 26219614 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Ketamine and Saline)
Number of subjects: 20
Study 24439245 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary nerve block (Ax group)
Number of subjects: 36
Study 24439245 — intervention group
Group type: COMPARATOR
Intervention: Portal site injections of local anesthetic (Lo group)
Number of subjects: 36
Study 22687265 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help cognitive behavioural therapy (CBT) for four weeks
Number of subjects: 70
Study 22687265 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 70
Study 19604351 — intervention group
Group type: EXPERIMENTAL
Intervention: Self administered version of the 'Business in Mind' program
Number of subjects: 249
Study 19604351 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone facilitated version of the 'Business in Mind' program
Number of subjects: 249
Study 19604351 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (psychoeducation only)
Number of subjects: 249
Study 19604351 — intervention group
Group type: EXPERIMENTAL
Intervention: Subordinate perceptions of manager support
Number of subjects: 249
Study 19604351 — intervention group
Group type: EXPERIMENTAL
Intervention: Absenteeism and presenteeism rates
Number of subjects: 249
Study 17587301 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month reference period (RP-1)
Number of subjects: 215
Study 17587301 — intervention group
Group type: COMPARATOR
Intervention: 12-month reference period (RP-12)
Number of subjects: 215
Study 15167957 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ToF and non-sustained VT
Number of subjects: 23
Study 15167957 — intervention group
Group type: COMPARATOR
Intervention: Patients with ToF (all)
Number of subjects: 23
Study 12195171 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide Dynamic Range Compressor (WDRC)
Number of subjects: 360
Study 12195171 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear Peak Clipper
Number of subjects: 360
Study 12195171 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Limiter
Number of subjects: 360
Study 12195171 — intervention group
Group type: COMPARATOR
Intervention: All circuits
Number of subjects: 360
Study 12195171 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear Compression-Limited Circuit
Number of subjects: 360
Study 9539490 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradually increased slow balloon inflation
Number of subjects: 207
Study 9539490 — intervention group
Group type: COMPARATOR
Intervention: Fast balloon inflation
Number of subjects: 207
Study 7635601 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day diet recalls (7DDR)
Number of subjects: 0
Study 7635601 — intervention group
Group type: COMPARATOR
Intervention: 24-hour diet recalls (24HR)
Number of subjects: 0
Study 7635601 — intervention group
Group type: EXPERIMENTAL
Intervention: Social desirability score
Number of subjects: 0
Study 2297191 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPSS)
Number of subjects: 86
Study 2297191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 379931 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment complemented by injections of poly A‐poly U
Number of subjects: 159
Study 379931 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 159
Study 379931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapeutic groups
Number of subjects: 159
Study 379931 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment and poly A‐poly U
Number of subjects: 159
Study 379931 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy in patients with lymph node involvement
Number of subjects: 159
Study 379931 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SS factor
Number of subjects: 159
Study 30640238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash-based physical therapy
Number of subjects: 48
Study 28654954 — intervention group
Group type: EXPERIMENTAL
Intervention: Branded lamotrigine
Number of subjects: 50
Study 28654954 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic lamotrigine 1
Number of subjects: 50
Study 28654954 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic lamotrigine 2
Number of subjects: 50
Study 28654954 — intervention group
Group type: COMPARATOR
Intervention: All three products
Number of subjects: 50
Study 25978169 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 (2 g/d for 7 days)
Number of subjects: 24
Study 25978169 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 (single dose of 2 g)
Number of subjects: 24
Study 25978169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 25978169 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 (both single and repeated administration)
Number of subjects: 24
Study 25978169 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104
Number of subjects: 24
Study 23359358 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (68% vertical-banded gastroplasty, 19% banding, and 13% gastric bypass)
Number of subjects: 4047
Study 23359358 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 4047
Study 21245461 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted performance feedback (supplemental report on the 'top 3' hospital-specific performance gaps)
Number of subjects: 149
Study 21245461 — intervention group
Group type: COMPARATOR
Intervention: Standard performance feedback reports
Number of subjects: 149
Study 19526798 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) group (group A) - one dose of TCM every day
Number of subjects: 70
Study 19526798 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group (group B) - subcutaneous injection of low‐molecular‐weight heparins calcium (LMWH)
Number of subjects: 70
Study 17722820 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Zhigou (TE 6) for 4 weeks
Number of subjects: 0
Study 17722820 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture at non-acupoint for 4 weeks (Control)
Number of subjects: 0
Study 15033608 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitor therapy (ACEI)
Number of subjects: 20
Study 11597289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antithrombin III (30,000 IU in total over 4 days)
Number of subjects: 2314
Study 11597289 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1% human albumin)
Number of subjects: 2314
Study 11597289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antithrombin III (30,000 IU in total over 4 days) with concomitant heparin
Number of subjects: 2314
Study 11597289 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1% human albumin) with concomitant heparin
Number of subjects: 2314
Study 9874886 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PowderJect (OPJ) with powdered lidocaine hydrochloride
Number of subjects: 14
Study 9874886 — intervention group
Group type: COMPARATOR
Intervention: Sham OPJ (empty)
Number of subjects: 14
Study 9874886 — intervention group
Group type: COMPARATOR
Intervention: Control site (untreated)
Number of subjects: 14
Study 8033368 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid withdrawal
Number of subjects: 9
Study 2917116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 30
Study 2917116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 30
Study 2917116 — intervention group
Group type: COMPARATOR
Intervention: No H2-blocker
Number of subjects: 30
Study 803184 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 8
Study 803184 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate
Number of subjects: 8
Study 803184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 803184 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate vs Caffeine
Number of subjects: 8
Study 31910748 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroidism
Number of subjects: 480698
Study 31910748 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased TSH
Number of subjects: 480698
Study 31910748 — intervention group
Group type: EXPERIMENTAL
Intervention: TPOAb
Number of subjects: 480698
Study 30431563 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive preoperative regimen (SDD, probiotics, and smectite)
Number of subjects: 30
Study 30431563 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 28345387 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment (NF + MED)
Number of subjects: 130
Study 28345387 — intervention group
Group type: EXPERIMENTAL
Intervention: MED alone
Number of subjects: 130
Study 28345387 — intervention group
Group type: EXPERIMENTAL
Intervention: NF alone
Number of subjects: 130
Study 26244887 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 56
Study 26244887 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol
Number of subjects: 56
Study 26244887 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions (increasing FIO2 to 1.0 and increasing PETCO2 to 45 mmHg)
Number of subjects: 56
Study 24102295 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaming console exercise in addition to usual therapy
Number of subjects: 21
Study 24102295 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy alone
Number of subjects: 21
Study 20935613 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol TCI (group P)
Number of subjects: 78
Study 20935613 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (group S)
Number of subjects: 78
Study 20935613 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study 18583331 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening (PGS) using FISH analysis for chromosomes X, Y, 13, 16, 18, 21, and 22
Number of subjects: 109
Study 18583331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGS)
Number of subjects: 109
Study 15877932 — intervention group
Group type: EXPERIMENTAL
Intervention: scopolamine (0.4 mg i.m.)
Number of subjects: 12
Study 15877932 — intervention group
Group type: EXPERIMENTAL
Intervention: mecamylamine (15 mg)
Number of subjects: 12
Study 15877932 — intervention group
Group type: EXPERIMENTAL
Intervention: mecamylamine (15 mg)/scopolamine (0.4 mg i.m.)
Number of subjects: 12
Study 15877932 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 12946658 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomniacs (n = 17)
Number of subjects: 62
Study 12946658 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients (n = 14)
Number of subjects: 62
Study 12946658 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n = 31)
Number of subjects: 62
Study 10389124 — intervention group
Group type: EXPERIMENTAL
Intervention: Eperisone hydrochloride (50 mg t.i.d.)
Number of subjects: 157
Study 8735069 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise at 60% of VO2max for 10 minutes
Number of subjects: 8
Study 8735069 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise exposure (third-octave band noise of 102 dB SPL centered at 2 kHz) for 10 minutes
Number of subjects: 8
Study 8735069 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of noise exposure and exercise for 10 minutes
Number of subjects: 8
Study 8735069 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise without noise exposure
Number of subjects: 8
Study 1868681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime prophylaxis (one or three doses)
Number of subjects: 3023
Study 6809475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg p.o.)
Number of subjects: 6
Study 30793412 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete stop of acute medication (programme A)
Number of subjects: 72
Study 30793412 — intervention group
Group type: COMPARATOR
Intervention: Restricted intake of acute medication (programme B)
Number of subjects: 72
Study 30254745 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal phone group
Number of subjects: 749
Study 30254745 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal control group
Number of subjects: 749
Study 30254745 — intervention group
Group type: COMPARATOR
Intervention: Cross-sectional control group
Number of subjects: 749
Study 28017399 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vaccine (1.6 × 10^11 viral particles)
Number of subjects: 500
Study 28017399 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vaccine (8.0 × 10^10 viral particles)
Number of subjects: 500
Study 28017399 — intervention group
Group type: COMPARATOR
Intervention: Placebo (containing only vaccine excipients)
Number of subjects: 500
Study 28017399 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vaccine
Number of subjects: 500
Study 28017399 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vaccine
Number of subjects: 500
Study 28017399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 25827693 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 668
Study 25827693 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump beating heart (OnP-BH)
Number of subjects: 668
Study 25827693 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional on-pump CABG (OnP)
Number of subjects: 668
Study 23237314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 18 mg
Number of subjects: 604
Study 23237314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study 20672723 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandio (nanohybrid composite)
Number of subjects: 31
Study 20672723 — intervention group
Group type: EXPERIMENTAL
Intervention: Quixfil (low shrinkage posterior composite)
Number of subjects: 31
Study 20672723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Grandio and Quixfil
Number of subjects: 31
Study 18385328 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture deficient in dopamine precursors (tyrosine and phenylalanine)
Number of subjects: 19
Study 18385328 — intervention group
Group type: COMPARATOR
Intervention: Nutritionally balanced mixture
Number of subjects: 19
Study 16792582 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous SQ-standardized specific immunotherapy (SIT)
Number of subjects: 54
Study 16792582 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 54
Study 12862247 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vegetarian group
Number of subjects: 408
Study 12862247 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian group
Number of subjects: 408
Study 12862247 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus patients
Number of subjects: 408
Study 12862247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular disorders patients
Number of subjects: 408
Study 12862247 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 408
Study 11026947 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural techniques
Number of subjects: 0
Study 11026947 — intervention group
Group type: COMPARATOR
Intervention: Befriending
Number of subjects: 0
Study 8797032 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise test in athletes
Number of subjects: 31
Study 8797032 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise test in non-athletes
Number of subjects: 31
Study 8231903 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated equine oestrogens (CEE) cyclically + 2.5 mg MPA sequentially for the last 12 days
Number of subjects: 90
Study 8231903 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms/day transdermal oestradiol cyclically + 2.5 mg MPA sequentially for the last 12 days
Number of subjects: 90
Study 8231903 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day CEE continuously + 2.5 mg MPA sequentially for the last 12 days
Number of subjects: 90
Study 8231903 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day CEE + 2.5 mg/day MPA continuously
Number of subjects: 90
Study 8231903 — intervention group
Group type: COMPARATOR
Intervention: Treatment-free control group
Number of subjects: 90
Study 3544035 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque 300 (iohexol)
Number of subjects: 120
Study 3544035 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix 320 (ioxaglate sodium meglumine)
Number of subjects: 120
Study 3544035 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopaque Coronar 370 (metrizoate)
Number of subjects: 120
Study 29269199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed lipid emulsion composed of soybean oil, medium chain triglycerides, olive oil, and fish oil
Number of subjects: 230
Study 29269199 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil-based lipid emulsion (control)
Number of subjects: 230
Study 26905919 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release methylphenidate (n=26) thrice daily (10-20 mg per dose)
Number of subjects: 52
Study 26905919 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (n=26) once daily (0.5-1.2 mg/kg/day)
Number of subjects: 52
Study 25047046 — intervention group
Group type: EXPERIMENTAL
Intervention: Press needle acupuncture
Number of subjects: 75
Study 25047046 — intervention group
Group type: EXPERIMENTAL
Intervention: Press plaster acupressure
Number of subjects: 75